Key Points
- Director Robert Hershberg sold 30,664 ADPT shares at an average price of $24.40, generating approximately $748,202 and reducing his ownership by 39.64%.
- Adaptive Biotechnologies reported 21.5% year-over-year revenue growth to $71.55 million, exceeding estimates, but missed quarterly EPS expectations with a loss of $0.25 per share versus the projected $0.13 loss.
- Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and a $24.42 average price target, while the stock trades near its 52-week high amid substantial insider selling and continued company losses.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) Director Robert Hershberg sold 30,664 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $24.40, for a total transaction of $748,201.60. Following the transaction, the director owned 46,683 shares in the company, valued at approximately $1,139,065.20. This represents a 39.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Adaptive Biotechnologies Trading Down 0.2%
NASDAQ ADPT opened at $25.44 on Friday. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. Adaptive Biotechnologies Corporation has a 1-year low of $12.00 and a 1-year high of $26.16. The firm's fifty day simple moving average is $21.89 and its 200-day simple moving average is $17.28. The company has a market capitalization of $4.06 billion, a PE ratio of -62.05 and a beta of 2.08.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The firm had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. During the same period in the previous year, the business posted ($0.17) EPS. Adaptive Biotechnologies's revenue for the quarter was up 21.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.
Institutional Trading of Adaptive Biotechnologies
Institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at about $28,000. Allworth Financial LP acquired a new stake in Adaptive Biotechnologies in the 2nd quarter worth approximately $35,000. EverSource Wealth Advisors LLC lifted its holdings in Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after purchasing an additional 1,565 shares during the last quarter. KBC Group NV bought a new stake in Adaptive Biotechnologies during the first quarter worth approximately $45,000. Finally, Assetmark Inc. boosted its position in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company's stock worth $49,000 after purchasing an additional 2,708 shares during the period. Institutional investors and hedge funds own 99.17% of the company's stock.
Adaptive Biotechnologies News Roundup
Here are the key news stories impacting Adaptive Biotechnologies this week:
- Positive Sentiment: Analysts maintain a broadly constructive view, with five Buy ratings, one Hold and one Sell. BTIG Research and TD Cowen recently raised their price targets to $25 and $28, respectively, while the consensus rating remains “Moderate Buy.” Analyst and stock information
- Positive Sentiment: Institutional ownership remains high at 99.17%, and several hedge funds increased their positions, including Jennison Associates, which more than doubled its stake. Institutional ownership information
- Positive Sentiment: The company’s latest quarterly revenue reached $71.55 million, exceeding estimates of $65.44 million and increasing 21.5% year over year, supporting the growth case for its immune-receptor sequencing business. Quarterly results
- Neutral Sentiment: ADPT has rallied substantially, trading near its 52-week high and above both its 50-day and 200-day moving averages. However, the consensus price target of $24.42 is below recently reported trading levels, suggesting limited near-term upside based on current estimates.
- Negative Sentiment: Multiple insiders sold substantial positions: CEO Chad Robins sold approximately 600,000 shares for nearly $14.9 million across August 17–18, while Director Peter Neupert sold 124,690 shares for $3.14 million and Director Robert Hershberg sold 30,664 shares for $748,000. The transactions reduced the directors’ holdings by roughly 40%–49% and the CEO’s ownership by about 11%–13%, potentially weighing on investor confidence. Insider selling report
- Negative Sentiment: Adaptive Biotechnologies missed quarterly EPS expectations, reporting a loss of $0.25 per share versus the anticipated loss of $0.13. The company remains unprofitable, with analysts expecting a full-year loss of approximately $0.40 per share.
Wall Street Analysts Forecast Growth
ADPT has been the subject of several recent research reports. Guggenheim boosted their price target on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. TD Cowen lifted their target price on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. decreased their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, May 6th. Finally, BTIG Research increased their price target on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $24.42.
Read Our Latest Report on ADPT
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
